Evidence map›Paper›PMID 37581646›Full record

ArticleJournal of clinical immunology2023

A Novel CDC42 Variant with Impaired Thymopoiesis, IL-7R Signaling, PAK1 Binding, and TCR Repertoire Diversity.

Kristian Assing, Sofie E Jørgensen, Katrine S Sandgaard, Kerstin De Keukeleere, Marie B-Hansen, Mikkel S Petersen, Ulla B Hartling, Thanis M K-de Vaal, Christian Nielsen, Marianne A Jakobsen and 5 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Kristian Assing *Department of Clinical Immunology, Odense University Hospital (OUH), Odense, Denmark. Kristian.assing@rsyd.dk.
Sofie E Jørgensen *Department of Biomedicine, Aarhus University (AU), Aarhus, Denmark.
Katrine S SandgaardDepartment of Pediatrics, Aarhus University Hospital (AUH), Aarhus, Denmark.
Kerstin De KeukeleereDepartment of Biomedicine, Aarhus University (AU), Aarhus, Denmark.
Marie B-HansenDanish Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
Mikkel S PetersenDepartment of Clinical Immunology, Aarhus University Hospital (AUH), Aarhus, Denmark.
Ulla B HartlingDepartment of Pediatrics, Odense University Hospital (OUH), Odense, Denmark.
Thanis M K-de VaalDepartment of Biomedicine, Aarhus University (AU), Aarhus, Denmark.
Christian NielsenDepartment of Clinical Immunology, Odense University Hospital (OUH), Odense, Denmark.
Marianne A JakobsenDepartment of Clinical Immunology, Odense University Hospital (OUH), Odense, Denmark.
Eleanor WattInfection, Immunity and Inflammation Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Stuart AdamsInfection, Immunity and Inflammation Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Qin HaoDepartment of Clinical Genetics, Odense University Hospital (OUH), Odense, Denmark.
Christina FagerbergDepartment of Clinical Genetics, Odense University Hospital (OUH), Odense, Denmark.
Trine H MogensenDepartment of Biomedicine, Aarhus University (AU), Aarhus, Denmark. Trine.mogensen@biomed.au.dk.ORCID http://orcid.org/0000-0001-9180-4060
Odense University Hospital · DKAarhus University · DKAarhus University Hospital · DKGreat Ormond Street Hospital · GBStatens Serum Institut · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic variants in cell division cycle 42 (CDC42) can manifest with dysmorphic features, autoinflammation, hemophagocytic lymphohistiocytosis, and thrombocytopenia, whereas defective thymopoiesis is a rare disease manifestation. We report a novel CDC42 missense variant (c.46A > G, p.Lys16Glu) resulting in infection and HPV-driven carcinogenesis in the mosaic mother and impaired thymopoiesis and profound T cell lymphopenia in the heterozygous daughter identified through newborn screening for SCID. We found that surface expression of IL-7Rα (CD127) was decreased, consistent with reduced IL-7-induced STAT5 phosphorylation and accelerated apoptotic T cell death. Consistent with the vital role of IL-7 in regulating thymopoiesis, both patients displayed reduced T cell receptor CDR3 repertoires. Moreover, the CDC42 variant prevented binding to the downstream effector, p21-activated kinase (PAK)1, suggesting this impaired interaction to underlie reduced IL-7Rα expression and signaling. Here, we provide the first report of severely compromised thymopoiesis and perturbed IL-7Rα signaling caused by a novel CDC42 variant and presenting with diverging clinical and immunological phenotypes in patients.

Indexed as

Interleukin-7p21-Activated KinasesApoptosiscdc42 GTP-Binding ProteinHumansInfant, NewbornReceptors, Antigen, T-CellSignal Transductioncdc42 GTP-Binding ProteinCDC42 protein, humanInterleukin-7p21-Activated KinasesPAK1 protein, humanReceptors, Antigen, T-CellCDC42HPV carcinogenesisIL7 receptorInborn error of immunityLymphopeniaMosaic, T cell receptor diversityNewborn screening

Identifiers

PMID37581646
PMCPMC10661826
OpenAlexW4385827588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.